Theodora Mistras
Known title: Chief Financial OfficerCIK: 0002013495
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal. Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.
Transaction History
| EW | ▲ Buy | Grant | 87,595 | $0 | 7/9/2026 | View on chart |
| EW | ▲ Buy | Grant | 12,325 | $0 | 7/9/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 41,711 | $0 | 3/6/2026 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 23,067 | $327K | 3/6/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 2,071 | $0 | 3/6/2026 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 1,146 | $16K | 3/6/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 2,935 | $0 | 3/4/2026 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 1,624 | $24K | 3/4/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 31,149 | $0 | 3/4/2026 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 17,226 | $253K | 3/4/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 23,085 | $0 | 1/1/2026 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 13,395 | $167K | 1/1/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 2,175 | $0 | 1/1/2026 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 1,203 | $15K | 1/1/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 31,149 | $0 | 3/4/2025 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 17,226 | $161K | 3/4/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 1,323 | $0 | 3/4/2025 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 732 | $7K | 3/4/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 23,084 | $0 | 1/1/2025 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 12,876 | $160K | 1/1/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 981 | $0 | 1/1/2025 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 523 | $7K | 1/1/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
EW: FDA Flags High-Risk Device Recall After Patient Death
The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.
EW: FDA Flags High-Risk Device Recall After Patient Death. The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.